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CHAPTER I
REVIEW OF THE LITERATURE
Introduction
Colorectal cancer is one of the leading causes of cancer-related death in
the United States. Although a small percentage of human colorectal cancers
result from inherited gene defects which confer a strong predisposition for tumor
development, such as in familial adenomatous polyposis (FAP) and hereditary
nonpolyposis colorectal cancer (HNPCC), the majority of cases occur
sporadically as a result of the accumulation of somatic mutations. Mutations in
the adenomatous polyposis coli (APC) tumor-suppressor gene are responsible
for FAP and are observed in a majority of sporadic colorectal cancers, making
animal models with Ape gene defects ideal for studying this disease process.
Several animal models have been developed with targeted APC mutations, and
these models are useful in determining the effects of potential anti-tumorigenic
treatments in APC-driven intestinal tumorigenesis. The Apcf1inl+ mouse model is a
murine model of human FAP in which intestinal tumors develop spontaneously
throughout the intestinal tract that are sensitive to modulation of the arachidonic
acid pathway via cyclooxygenase (COX) inhibition. COX catalyzes the committed
step in the conversion of arachidonic acid to prostaglandins. There are two
isoforms of this enzyme, known as COX-1 and COX-2. COX-1 is constitutively
expressed in most tissues and is believed to be a housekeeping enzyme
involved in maintaining homeostasis. COX-2 is inducible in inflammatory
conditions and catalyzes the formation of prostaglandins involved in the
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promotion of tumorigenesis. Prostaglandins can be pro-inflammatory and appear
to be important in tumor progression. Intestinal tumors over-express COX-2, and
it has been proposed that this up-regulation confers a growth advantage to
tumors by promoting angiogenesis.
Resveratrol, a polyphenolic phytochemical found in red wine, has been
demonstrated to inhibit tumor growth in vitro in several immortalized human
colorectal cancer cell lines (1) and to inhibit COX-2 in human colorectal cancer
cells expressing mutated APC (2). However, discordant effects have been
reported regarding resveratrol's efficacy as a potential anti-tumorigenic agent in
vivo. While resveratrol inhibited the formation of aberrant crypt foci (ACF) in a
carcinogen-induced rodent model of colorectal cancer (3), it had no effect in a
murine xenograft model of leukemia (4). Therefore, our study was designed to
evaluate the anti-tumorigenic effect of dietary resveratrol in Ap<f1inl+ mice. These
mice (6-7 animals per group) were fed diets containing increasing levels of
resveratrol (4-90 mg per Kg BW) for seven weeks. Animals fed resveratrol at 90
mg per Kg BW had significant reductions in tumor biosynthesis of PGE2.
However, resveratrol had no effect on tumor number or tumor COX-2 expression.
Therefore, while resveratrol is a potent inhibitor of cell growth in vitro and inhibits
PGE2 biosynthesis in vivo, it was unable to reduce tumor load in Ap<f1inl+ mice.
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Colorectal Cancer
Background Information
Colorectal cancer is currently the third-leading cause of cancer-related
death in the United States for both males and females, and resulted in 56,700
deaths in 2001 (5). It is estimated that 135,000 new cases of colorectal cancer
are diagnosed each year (5), primarily in persons sixty years of age or more.
Approximately 50% of persons in Western populations will acquire a colorectal
tumor by the age of 70 as a result of the accumulation of somatic mutations over
time (5-6). These sporadic colorectal cancers account for 90% of all colorectal
cancers, while the remaining ten percent occur earlier in life in families with
germline defects resulting in strong predispositions for tumor development (7).

Sporadic Colorectal Cancers
Sporadic colorectal cancer is typically diagnosed in the sixth or seventh
decade of life, resulting in a decreased tumor load relative to the hereditary
colorectal cancers. Although most sporadic adenomas (90%) remain benign, ten
percent will progress to malignancy within five to ten years once they acquire
characteristics allowing them to penetrate the basement membrane and
metastasize to other tissues via the blood or lymphatic fluid (8-10). Several
factors have been identified that may increase the likelihood of developing
sporadic colorectal cancer, including a history of inflammatory bowel disease,
age (> 50 years), a high-fat, low-fiber diet, physical inactivity and obesity (11-15).
Although various mutations have been identified as contributors to sporadic
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colorectal cancer, mutations in APC are observed in approximately 80% of all
sporadic colorectal cancers.

Hereditary Colorectal Cancers
HNPCC, the most common form of hereditary colorectal cancer, accounts
for eight percent of all human colorectal cancer incidence (16). HNPCC is
generally diagnosed in the third or fourth decade of life and results in the
presence of multiple tumors, mostly in the proximal colon, which will most likely
progress to carcinoma (17). Extra-colonic tumors such as endometrial, ovarian,
and gastric tumors are also observed in these patients (17). Although mutations
in several genes, including APC have been observed in HNPCC (18-21), the
majority of mutations occur in genes involved in the correction of base-base
mismatch errors, known as the mismatch repair sy�tem (7-8).
When a base-base mismatch occurs, the error is recognized by the Mut S
homolog (MSH) complex, which recruits the Mut L homolog (MLH), a repairing
protein, to the site. Exo-nucleases remove the mismatched base, and a corrected
strand is inserted into the original strand by DNA polymerase and DNA ligase. In
HNPCC, loss of heterozygosity in either MSH (40% of cases) or MLH (50% of
cases) results in defects in the mismatch-repair system, increasing the survival of
downstream pro-tumorigenic DNA replication errors by 100 to 1000 fold and
promoting tumor development (22-24).
FAP occurs in families with a strong predisposition to colorectal cancer
development as a result of a germline mutation at chromosome five in one allele
4

of the adenomatous polyposis coli (APC) tumor suppressor gene (25-30).
Adenoma formation results when a somatic mutation occurs in the remaining
wild-type allele, resulting in loss of heterozygosity and translation of a non
functional, truncated APC protein product (27,31 ). FAP accounts for only one
percent of all heritable colorectal cancers but results in a 100% chance of
developing hundreds to thousands of colorectal adenomas by the second decade
of life with a high likelihood of progression to adenocarcinomas (32-33).
Depending on the location of the APC mutation, extra-colonic tumors may
develop in the form of retinal lesions, osteomas, skin desmoids, and brain tumors
(35-36). The location of the mutation also dictates the age of onset and the
severity of the disease (36-40). It appears that mutations occurring in the center
regions of APC (known as the mutation cluster region) result in the most severe
phenotypes, while mutations in the first third and last third of the gene are
associated with decreased severity (41-42).
FAP may be categorized into three phenotypes (based on severity) as
profuse, severe and attenuated FAP {Table 1-1, p.6). Profuse FAP is the most
severe phenotype, and results in the formation of greater than 5,000 colonic
tumors due to a mutation at exon 15, between codons 1255 and 1467 in the
center of APC, (42). In severe FAP, the APC mutation occurs between codons
600-1600 and result in the formation of 2,000-5,000 colonic tumors (43). In the
least severe form, attenuated APC (AAPC), mutations occur upstream of codon
200 or downstream of codon 1600 of APC, resulting in the formation of 1002,000 polyps (41, 44-48). The decreased severity observed in AAPC is due
5

Table 1-1. FAP Phenotypes and Characteristics.
# Tumors

Profuse FAP

Mutation Location
(codon)
1255-1467

Severe FAP

600-1600

2,000-5,000

Attenuated FAP

200-1600

100-2,000

Syndrome

> 5,000

to the location of the mutatin towards the outer ends of APC, allowing the
expression of a functional protein product (49).

Adenomatous Polyposis Coli

f

APC is a tumor suppressor gene expressed by non-dividing cells at the
upper region of the crypts and along the villus of the small intestine and
colorectal epithelium (50). It functions as a regulator of intestinal cell migration
and cell-cell adhesion, and when APC is truncated in normal intestinal tissue, in
vivo cell migration is inhibited, resulting in tumor formation (51-53).
The APC mutation is believed to be an early event in intestinal
tumorigenesis, and mutations in this gene are frequently observed in tumors from
sporadic, HNPCC, and FAP patients (29, 35, 54-60). More than 80% of colonic
tumors taken from sporadic colorectal cancer patients and 100% of tumors taken
from FAP patients express mutated APC (61). The relatively high frequency of

APC mutations observed in various forms of colorectal cancers and the early role
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of APC in the tumorigenic process suggest that animal models with germline Ape
mutations would be ideal in studying Ape-driven intestinal tumorigenesis.
APC regulates cell-cell adhesion and cell migration by promoting the
degradation of the transcriptional activator, P-catenin, through the Wnt signaling
pathway (62-64). Nuclear P-catenin is an activator of pro-tumorigenic
transcription factors and its expression is increased in primary and metastatic
tumors from sporadic colorectal cancer patients (66). Mutations in APC
frequently occur at the P-catenin binding domains, altering the ability of APC to
regulate P-catenin via the Wnt signaling pathway (Figure 1-1, p. 8) (66). In this
pathway Wnt binds to its cell surface receptor, frizzled (fzd) (67) and activates
disheveled (dsh), which then inactivates glycogen synthase kinase-3-P (GSK3P)
(63). Active GSK3P forms a complex with APC and its scaffolding protein, axin,
and this complex facilitates GSK 3 p-mediated phosphorylation of p-catenin,
earmarking it for ubiquitination by the E3 ubiquitin ligase and subsequent
degradation in the proteosomes (68). When GSK3P is inactivated by the Wnt
signaling cascade, p-catenin accumulates in the cytosol and eventually
translocates to the nucleus where it promotes the activation of pro-tumorigenic
transcription factors such as T-cell factor/lymphoid enhancer factor (Tcf/Lef) (63);
(68-72). Animal models of FAP, such as the Ape Minl+mouse, have increased
expression of p-catenin due to the defect in Ape. Non-steroidal anti-inflammatory
drugs (NSAIDs), proven to be effective in inhibition of tumorigenesis in these
animals, normalize expression of p-catenin (73).
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Apoptosis

Proliferation

Figure 1-1. The Wnt Signaling Cascade
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Models of Intestinal and Colorectal Cancer
Several animal models are used in the study of the initiation, progression
and treatment of colorectal cancer. Popular models of colorectal cancer and their
characteristics may be found in Table 1-2 (p.10).
C57BU6J APd'inl+ Mouse
A murine model of human FAP was derived through an N-ethyl-N
nitrosurea (ENU)-induced mutation at the 15th exon of murine Ape in a C57BU6J
mouse. This mutation resulted in the formation of multiple intestinal neoplasia
(min), and thus the Ap�inl+ mouse model (31, 74). The Ap�inl+ mouse carries a
nonsense mutation in Ape at nucleotide 2549, substituting TTG with a stop codon
(TAG) (75). This substitution results in the truncation of the Ape protein from
300kD to 95kD, and subsequent protein dysfunction leading to tumor
development (31, 45). These mice develop 40-50 adenomas, mostly in the small
intestine, which typically do not progress to carcinomas. However, this severe
tumor load results in a shortened lifespan of up to 150 days due to anemia or
intestinal obstruction (75). The Ape defect in the Ap�inl+ mouse makes it a
useful model in studying colorectal cancer, since this defect is present in 100% of
human FAP and 80% of human sporadic colorectal cancer patients (56, 76).
Other models of Ape-directed tumorigenesis
Other models of Apo-directed tumorigenesis have been developed
through target mutations in different regions of Ape, resulting in some variations
in phenotype, but these animals typically display similar patterns of
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Table 1-2. Animal Models of Human Colorectal Cancers and their
Characteristics
Animal
Model

Earliest
Genetic
O r::r: .._:

Tumor
Location

Tumor
Multiplicity

Aberrant
Crypt Foci

Neoplastic
Progression

Yes

Yes

AOM

/3-

Colon

1638T
Apd1

Ape

None

None

No

N/A

N

Ape

Small Intestine,
Follicle,
Skin

5-6

No

No

474

Ape

Intestine &
Breast

� 30 per mouse

No

No

so
Apd15

Ape

None

None

No

N/A

7 6
Apd1 1

Ape

Small Intestine
> Colon

200-300

No

No

Ape

Small Intestine
> Colon

� 30 per mouse
( < 4 colonic)

No

No

eatenin,
Ras>>>A

638
Apd1 1

Apd1

AP<fd

inl+

< 1-3 per animal

tumorigenesis as those observed in the Apcf1in1+ mouse. A mutation at amino acid
716 of

Ape results in the formation of the Apcf716 mouse model (77).

Homozygotes are embryonic lethal, and by three weeks of age, heterozygotes
develop micro-adenomas from the duodenum to the rectum. By sixteen weeks of
age, 200 to 300 polyps are present, predominantly in the small intestine, ranging
in size from 0.2 to 5 mm, and these polyps are sensitive to selective COX-2
inhibition and PGE2 receptor (EP2) antagonism (79-80).
Mutations in Ape at exon 10 result in the truncation of the protein at 474
amino acids and the formation of the Apd- 474 mouse model. These animals have
a phenotype similar to the Apcf1inl+ mouse with the exception of the presence of
mammary tumors in 18% of the animals and tumors in these animals are also
sensitive to COX-2 inhibition (81).

Apc1 1638 mice were developed through a targeted mutation at amino acid
1638 on Ape (82). Two forms of this model exist; Apc1 1638N and Apc1 1638 r.

Apc1 1638N animals have no detectable Ape protein expression, resulting in fully
penetrant multifocal cutaneous follicular cysts and desmoids in addition to
attenuated polyposis of the upper GI tract (82). Apc1 1638T animals express a
truncated protein product of 182 kD, but both heterozygotes and homozygotes
are tumor-free, with no increased predisposition for tumor development,
·suggesting that truncation of APC at 182 kD results in production of a functional
protein (83).
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The Azoxymethane-induced Model of Colorectal Cancer
The azoxymethane (AOM)-induced model of colorectal cancer is derived
through the administration of a bolus dose of the colon carcinogen AOM,
resu lting in a sequence of somatic mutations which lead to the formation of
precancerous lesions, or aberrant crypt foci (ACF) in the colon. If left untreated,
these ACF will progress to colorectal adenocarcinomas (82-84) . AOM models
typically develop one to three tumors after four weeks of treatment with 1 0 mg
AOM per Kg body weight. Mutations in Ape and P-catenin are frequently present
in tumors in this model (85) , and like the Ap<f1inl+ mouse, ACM-ind uced tumors
also over-express COX-2 and are sensitive to COX inhibition and PG E2 receptor
antagonism (86) .

The Arachidonic Acid Cascade and Intestinal Tumorigenesis
Introduction
The enzymatic action of cyclooxygenase (COX) on ·arachidonic acid
results in the formation of prostaglandins, which have been impl icated in the
promotion of intestinal tumorigenesis (87). Arachidonic acid (20:4 n-6) , whether
obtained directly from the diet or synthesized from linoleic acid ( 1 8:2 n-6) is
stored in its esterified form in cell membrane phospholipids. Arachidonic acid is
cleaved from membrane phospholipids by various phospholipases, namely
cytosol ic phosphol ipase A2 (cPLA2), and serves as the substrate for COX in the
formation of eicosanoids (88) . The rate-limiting step in the formation of the pro
tumorigenic prostaglandins is the release of arachidonic acid from membrane
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phospholipids by various phospholipase A2s. Initially, cytosolic phospholipase A2
(cPLA2) binds to the membrane phospholipid where it cleaves the sn2 ester bond
linking arachidonic acid to the glycerol backbone. cPLA2 has been implicated in
the promotion of colorectal tumorigenesis through its role in providing the
substrate for the formation of pro-inflammatory prostaglandins (89). When cPLA2
is knocked out in Apd1 716 mice, intestinal polyp size is decreased, but no effects
on intestinal tumor number are observed (90). However, in Apdvfinl+ mice, the
absence of cPLA2 expression results in an 83% decrease in small intestinal
tumor number compared to animals expressing normal cPLA2 (91). These effects
are sim ilar to decreases observed in dual Ap<fv1inl+1cox-2 -i- mice.

Cyclooxygenase

COX catalyzes the irreversible step in the formation of prostaglandins from
arachidonic acid in a two-part cyclooxygenase-peroxidase reaction (Figure 1-2 ,
p.14). In the first reaction, arachidonic acid binds to the cyclooxygenase active
site. A tyrosyl radical (Tyr-385) abstracts the pro-S hydrogen at C13, generating
an endoperoxide via radical rearrangement. Following further rearrangement to
C15, the radical attacks molecular oxygen, genera.ting PGG2, a peroxide
intermediate. PGG2 migrates to the peroxidase active site where it is reduced to
PGH2, the parent compound for further conversion to thromboxane, prostacyclin,
or prostaglandins by the action of specific synthases.
Two isoforms of COX exist, which share 60% homology between and
within species, but differ in their patterns of expression (92). COX-1 is

13
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Hydroperoxidase

!

PGE2 Synthase

Figure 1-2. The Arachidonic Acid Cascade

constitutively expressed in most tissues as a housekeeping enzyme and is
involved in maintain ing tissue integ rity under normal conditions. Th is fu nction is
evident by the increased incidence of gastric ulce ration following COX- 1
in hibition (93-95). The physiological role of COX- 1 in intestinal tumorigenesis was
investigated through animal knockout models. When COX- 1 was knocked out in
C57BU6J mice , an imals had a normal l ifespan , normal fe rtility, decreased
platelet agg regation and we re less sensitive to rad iation injury compared to
controls, but their offspring were embryonic lethal (96) . When COX- 1 was
knocked out in Apc"Ainl+ mice, tumor load was decreased by 80%, and PGE 2
14

biosynthesis was decreased by 99% (97-98). However, no signs of gastric
ulceration or kidney anomalies were observed.
COX-2 is constitutively expressed in the brain and kidneys, but is inducible
in other tissues by pro-inflammatory cytokines, growth factors, and tumor
promoters (92). Induced expression of COX-2 has been reported in human
prostate and gastric tumors as well as in intestinal tumors (99) from hereditary
and sporadic human colorectal cancers (100-103), and this phenomenon is
observed in 85% of adenocarcinomas and in 50% of benign polyps. COX-2
expression is also induced ·in the intestinal tumors of Ap<f1in!+ mice (104) and in
the carcinogen-induced colonic tumors of rodent models (1 05).
Selective targeting of the COX-2 gene results in survival of only 60% of
pups afflicted with kidney anomalies leading to end-stage-renal disease and
female infertility (98). When COX-2 is knocked out in Ap<f1inl+ mice, tumors are
decreased by 75% compared to controls (106) and tumorigenesis in dual
Apcf 716/COX-2 null mice is reduced by 34% compared to controls (107).
Inhibition of COX-2 has proven to be effective in vitro and in vivo in the
prevention of colorectal cancer (108-110). NSAI D-induced selective COX-2
inhibition in Ape Mini+ mice results in an 80%-86% decrease in polyps as
compared to controls (111). Increased expression of COX-2 is associated with
increased angiogenesis and cell motility through a matrix, two factors which are
critical for the growth and metastasis of tumors _ (112). Selective COX-2 inhibition
with NSAIDs attenuates the increased risk of angiogenesis and metastasis
associated with induction of COX-2 in human colorectal cancers (113), and
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induces apoptosis of human colorectal cancer cells in vitro (112, 114-115). The
promotion of angiogenesis and tumor integrity by COX-2 induction in tumors is
due in part to the production of prostaglandins, which promote the expression of
pro-angiogenic factors such as vascular endothelial growth factor (VEGF) (111).
Selective inhibition of COX-2 expression in a murine xenograft model of Lewis
lung carcinoma cells resulted in a significant reduction in tumor growth and a
94% reduction in expression of VEGF (116).
Decreases in tumorigenesis achieved with the administration of NSAIDs in
animal models of human colorectal cancer are related to the inhibition of COX
and subsequent decreases in the biosynthesis of prostaglandin E2 (PGE2 ).
NSAI Ds inhibit the formation of prostaglandins by inhibiting COX (117),
decreasing tumor load in Apcf1inl+ mice (118). In animal models of human FAP,
COX inhibition with NSAIDs decreases APC-mediated intestinal tumorigenesis
by 85-99% (119-121). Similar effects are observed when COX is inhibited in
carcinogen-induced models of colorectal cancer (122-123), and decreases in
PGE2 synthesis have been correlated with increased responsiveness to
chemotherapy in human FAP patients (124). The role of PGE2 in the promotion
of tumor integrity was bolstered by the rescue of Apcf1inl+ mouse tumors from
NSAI D-induced regression with administration of PGE2 (125), and the
acceleration of intestinal polyposis via PGE2 receptor agonism in Apcf 716 mice
(126). However, NSAI D-induced regression of ACF and APC-driven tumors is not
totally dependent on PGE2 synthesis (120, 127-129). Reductions in intestinal
tumors of Apcf1inl+ mice by 95% with sulindac, were not associated with any
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significant changes in PGE2 in normal tissue (121 ), suggesting that
tumorigenesis is not entirely dependent on prostaglandin levels and that there is
a prostaglandin-independent mechanism in driving NSAI D-induced tumor
inhibition.
Phytochemicals
Epidemiological evidence indicates that increased consumption of fruits
and vegetables may decrease the risk for developing colorectal cancer (130131). It is believed that in addition to the high fiber and low fat content of these
foods, phytochemicals may be partly responsible for the beneficial health effects
(132). Structures of several phytochemicals recently investigated for their
chemopreventive properties are illustrated in Figure 1-3, (p. 18).
In the human diet, the majority of these beneficial phytochemicals are
found in fruits and vegetables, wine and tea, and soy products, with average
daily intakes ranging from one to two grams (133). Extracts from black tea and
red wine have been shown to decrease intestinal carcinogenesis in an AOM
induced rat model of colorectal cancer (134-135). Evidence suggests that
dehydrated red wine solids contain high levels of phytochemicals which may
display chemopreventive properties. Red wine solids have been shown to
detoxify carcinogens in vitro and delay tumor growth in a carcinogen-induced
model of colorectal cancer (136-138). These red wine solids consist of various
polyphenolic phytochemicals, and estimated levels of total polyphenols in red
wine range from 100 to 300 mg per liter, with the highest levels being found in
Cabernet Sauvignon wines (Table 1-3, p. 18) (139-141).
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Figure 1-3. Structures of Polyphenolic Phytochemicals
Table 1-3. Phytochemical Profile of Red Wine
Phytochemical
Classification
Cinnamates (Cinnamic Acid)
Gallates (Gallic acid)
Flavanols (Resveratrol)
Catechins
Malvidins

Quantity (mg per ml)
4-80
20-40
40-80
75-115
60- 110
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Numerous studies indicate that phytochemicals inhibit tumorigenesis in
several immortalized cell lines and in animal models of colorectal cancer ( 142;
144). Two soy isoflavones, genistein and daidzein, prevented the formation of
aberrant crypt foci in a carcinogen-induced rodent model of colorectal cancer
(145-146). Curcumin, quercetin and rutin inhibited the formation of AC F in AOM
induced rodent models of colorectal cancer (84, 147-150) . Studies conducted in
the Apd'inl+ mouse model indicate that catechin and curcumin decreased
intestinal tumorigenesis. However, in the same study, quercetin and rutin had no
effect.

Resveratrol
Resveratrol is a naturally_ occurring polyphenolic compound that is found in
relatively high quantities in peanuts and in the skins of grapes used in preparing
red wines ( 151-155) . Levels of this compound in red wine range from 0.3 to 7. 1 7
mg/L ( 156- 157) . Resveratrol is synthesized in plants in times of stress, offering
protection from fungal infections, by the action of resveratrol synthase on
coumaroyl CoA and malonyl CoA ; a reaction that produces resveratrol, CoA, and
CO2 ( 158- 159) (Figure 1-4, p. 20) .

· Resveratrol and Tumorigenesis
Resveratrol inhibited the growth of several immortalized human colorectal
- cancer cell lines and inhibited tumorigenesis in animal models of human
colorectal cancer (186-187). Several mechanisms have been proposed to explain
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4 Coumaroyl CoA + 3 Malonyl CoA
Resveratrol
Synthase

Resveratrol

+ 4 CoA + 4 CO2

Figure 1-4. Synthesis of Resveratrol

these effects, including antioxidant and antimutagen activity, inhibition of cell
cycle progression and modulation of the arachidonic acid cascade (162, 186187).
Antioxidants inhibit carcinogenesis by protecting cells from the DNA
damaging effects of free radicals in vitro and in vivo (160-161). Resveratrol
possesses potent antioxidant activity compared to a-tocopherol in Cu 1 + induced
human _LDL oxidation (162) and in vitro, resveratrol prevented free-radical
induced damage to DNA and RNA (163-166). Free radical formation induced by
12-0- tetradecanoylphorbol-13-acetate (TPA) in human promyelocytic leukemia
cells is inhibited by resveratrol in a dose-dependent manner (167).
Resveratrol prevents cellular damage by detoxifying carcinogens in vitro
(168-171). In v·ivo, resveratrol prevents the development of ACF induced by 7,12dimethylbenzanthracene (DMBA) in a dose-dependent manner (172-173). This
inhibition of carcinogen-induced tumor initiation is believed to occur via a
cytochrome p450 pathway. Resveratrol has been demonstrated to competitively
bind to the aryl hydrocarbon receptor (AhR), antagonizing the transcription of
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pro-tumorigenic genes such as CYP1A1 induced by AhR ligands, such as DMBA
and TPA in vitro (174-175).
In addition to antioxidant and antimutagenic activity, many in vitro studies
report that resveratrol induces apoptosis and inhibits the growth of colorectal
cancer cells by disrupting cell cycle progression (Figure 1-5, p. 22) at the S/G2
phase transition (176-182). Cyclins are synthesized continuously, accumulating
as the cell cycle advances, and are destroyed at defined points. As the cyclins
build up, they signal progression into the next phase of the cell cycle, acting as
the 'internal timekeepers' of the cell. For entry into the S-phase, the cell must
execute DNA synthesis and mitosis. Resveratrol may impede tumor cell
proliferation by causing an arrest in the S-phase of the cell cycle, disrupting the
S- to G2 phase transition as demonstrated by an absence of G2/M phase
associated cyclins and an increase in G1 and S phase-associated cyclins, forcing
cells to undergo apoptosis (180-181, 183-189).
As mentioned previously, inhibition of COX by NSAI Ds inhibits
tumorigenesis in several models of human colorectal cancer, and the
antitumorigenic effects attributed to resveratrol may be mediated through its
ability to modulate the formation of prostaglandins by inhibiting COX (190-192).
Several phenolic compounds have been shown to decrease tumorigenesis
through modulation of the arachidonic acid pathway (142, 193). Curcumin,
quercetin, kaempferol, genistein, apigenin, resveratrol and resorcinol have all
been shown to inhibit COX-2 activity and decrease formation of prostaglandins
(2, 194). Resveratrol down-regulates the expression and activity of COX-2 in vitro
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( 1 90- 1 9 1 , 1 95) . Resveratrol also inhibits the formation of prostaglandins by
regu lating the release of arach idon ic acid from membrane phospholipids (1 96) .
Resveratrol may inhibit COX-2 expression and tumor cel l growth by inh ibiting the
activation of NFKB , a transcriptional regulator of COX-2 and other pro
tumorigenic factors. NFKB is a transcriptional regulator implicated in the
activation of genes involved in intestinal cell migration, and proliferation and is
normally sequestered in the cytoplasm by the IKK complex consisting of I KKa,
I KK� , and NFK�-essential modulator (N EMO) (1 97) . The TN Fa signaling cascade
leads to the phosphorylation of I KKa, earmarking the IKK complex for degradation
in the proteosomes by the E3 ubiquitin ligase. Deg radation of the I KK complex
resu lts in the release and nuclear translocation of sequestered NFK� ( Figure 1-6 ,
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p. 24), an action inhibited when degradation of the In: complex is repressed.
This nuclear translocation results in the activation of target genes such as c-Jun,
c-Fos, c-myc, Ras, ICAM, VCAM, COX-2, iNOS, which are involved in the
tumorigenic process (198). The up-regulation of these factors culminates in
decreased apoptosis, increased proliferation, and increased angiogenesis and
overall, promotes tumorigenesis and tumor integrity.
In vitro evidence suggests that resveratrol inhibits proliferation and
induces apoptosis of colorectal cancer cells by inhibiting NFK:� activation. In
epithelial cells, resveratrol inhibits phosphorylation of IK:�, preventing degradation
of the I K:K: complex and subsequent NFK:� translocation to the nucleus in a dose
dependent manner as evidenced by decreased nuclear content of NFK:� (1 99200). These effects result in decreased NFK:�-dependent reporter gene
transcription (201). Similar effects have been observed with other
phytochemicals, such as capsaicin and curcumin, and curcumin and resveratrol
blocked nuclear NFK:�-induced transcription of COX-2 by inhibiting the
degradation of I K:�a (202).
As discussed previously, selective COX-2 inhibition impedes intestinal
tumorigenesis by decreasing prostaglandin biosynthesis and prostaglandins are
involved in the maintenance of tumor integrity by promoting angiogenesis and
metastasis. Resveratrol and other polyphenolic phytochemicals with similar
resorcin-containing structures have been shown to inhibit COX-2 and impede
tumorigenesis by inhibiting the metastatic process in vitro and in vivo (203).
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Resveratrol has been demonstrated to inhibit lung metastasis a�d
capillary-like network formation (a measure of angiogenesis) in human umbilical
vein endothelial cells (HUVECs) (204) and to decrease tumor volume, weight,
and metastasis to lung in mice xenograft models of lewis lung carcinoma (205).
In addition to these reports indicating metastatic inhibition, in vitro data in two
breast cancer cell lines (MDA-MB-435, a highly invasive cell line and MCF-7, a
non-invasive cell line) indicates that resveratrol may possess a higher affinity for
those cells with greater invasive capacity (206-207).
Due to its polyphenolic ring structure, and similarity to diethylstilbesterol
(DES) (Figure 1-7, p. 25), resveratrol has been examined for a potential role as a
phytoestrogen and has been shown to modulate mammary tumorigenesis. In
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addition to its inhibition of COX-2 transcription and activity in human breast
cancer cells (194), resveratrol has estrogen antagonist activity (208), and inhibits
the proliferation of estrogen receptor-positive (ER+) MCF-7 breast cancer cells
(208-209). However, in the same cell line, other reports indicate that resveratrol
acts as an estrogen agonist, promoting cell growth (210-211).
The significance of its phytoestrogen activity in relation to colorectal
cancer centers around the fact that the gastrointestinal tract expresses ER� and
this expression is associated with estrogen-mediated modulation of intestinal
cancers (212). In CHO-K1 breast cancer cells, resveratrol-boL;Jnd E R� had
increased transcriptional activity compared to estrogen-bound E R�, indicating
that tissues, such as the intestine, that preferentially express E R� may be
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sensitive to the estrogen agonist activity of resveratrol (2 1 3) . However, the
affin ity of resveratrol for the ER is reported to be five orders of magnitude lower
than that of DES or estrogen (E 2) (2 1 4) . Therefore the role of resveratrol as an
estrogen agon ist via E R� in colorectal cancers is most likely insignificant as
compared to other proposed mechanisms.
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Chapter II
Effects of resveratrol on intestinal tumor load, COX-2 expression and PGE2
biosynthesis in a murine model of intestinal tumorigenesis

Abstract
To determ ine its effect on intestinal tumorigenesis and the pro-tumorigenic
COX-2 pathway in Apd'inl+ m ice, resveratrol was administered as a powdered
adm ixture in the diet at 0, 4, 20, or 90 mg per Kg body weight for seven weeks. In
two separate experiments, resveratrol had no effect on intestinal tumor load.
Resveratrol was demonstrated to be stable in the diet under experimental
conditions, circu lated in the plasma in the glucu ronide-conjugated form , and
reached the tumors as evidenced by sign ificant decreases in PGE 2 biosynthesis.
However, imm unohistochem ical staining of intestinal tumors revealed no
changes in COX-2 expression . This study demonstrates that resveratrol, as
provided ad libitum in the diet, does not modify tumorigenesis in Apd'inl+ m ice.

Introduction
Polyphenolic phytochemicals have been shown to be effective anti
tumorigen ic agents in several in vitro models (203) , and efficacy in vivo has also
been demonstrated when these compounds are provided in the diet (1 48, 2 1 52 1 6) . Resveratrol, a resorcinol-containing polyphenol found most commonly in
red wine, inhibits the growth of several immortalized human colorectal cancer cell
l ines (2 1 7-21 8) . When provided orally, resveratrol reduced tumor load in Lewis
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lung carcinoma-bearing mice (219) and reduced the number of aberrant crypt
foci in an azoxymethane (AOM)-induced rat model of colorectal cancer (220).
Quercetin, curcumin, and caffeic acid phenyl ester, chemical analogs of
resveratrol, inhibit intestinal tumorigenesis in vitro (221-222) and aberrant crypt
formation in vivo (2, 84). These polyphenolic phytochemicals share a common
resorcinol-containing structure, and this structure is believed to be partly
responsible for the reported effects (2, 223).
Resveratrol's anti-tumorigenic effects have been linked, in part, to
inhibition of cyclooxygenase (COX) catalyzed reactions (190, 192, 224-225).
COX catalyzes the committed step in the conversion of arachidonic acid to pro
tumorigenic eicosanoids, such as PGE2 , which are involved in the maintenance
of tumor integrity (125). COX-2 expression is up-regulated in 80-85% of human
adenocarcinomas and colonic tumors (100, 226-227) and in 80-85% in Apcfv1inl+ of
mouse adenomas (228). Resveratrol has been shown to inhibit COX-2 promoter
activity (224), down-regulate COX-2 expression (192, 224) and inhibit COX-2
activity (190, 229) in vitro.
Numerous studies have demonstrated the ability of COX inhibitors to
decrease tumor multiplicity in the ApcJv1inl+ mouse, an animal model possessing a
germline mutation in the adenomatous polyposis coli (Ape) tumor-suppressor
gene (230-233). These mice spontaneously develop an average of forty tumors
throughout the intestinal tract that are sensitive to COX inhibition. Murine Ape is
homologous to human APC (75), and patients with familial adenomatous
polyposis (FAP) have an autosomal dominant disorder with a germline mutation
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in one allele of the A PC tumor suppressor gene (27). Adenoma formation results
when a somatic mutation is acquired in the remaining functional allele. By the
time they reach their twenties, FAP patients typically develop hundreds to
thousands of intestinal adenomas, mostly in the colorectal mucosa, which are
also sensitive to COX inhibition (234). Similarly, at least one allele of A PC is
mutated in approximately 80% of sporadic colorectal cancers, making the
Apd--finl+ mouse a relevant model for studying the early stages of colorectal
cancer (66, 235-236).
The purpose of this study was to evaluate the dose-dependent effects of
dietary resveratrol on intestinal tumorigenesis in the Ap<f-1inl+ mouse, and to
determine whether tumor COX-2 levels and PGE2 biosynthesis are affected by
this treatment.

Materials and Methods
Animals
Male C57BU6J Apd--finl+ mice or wild type littermates (Jackson
Laboratories, Bar Harbor, ME, USA) were obtained following genotyping at 35
days of age and randomly assigned to their respective experimental groups.
Animals were provided water and diet ad libitum. Diet intake and overall health
was monitored daily and body '-Yeights were monitored weekly. All animal
research procedures were approved by the University of Tennessee Animal Care
and Use Committee and were in accordance with the NI H Guide for the Care and
Use of Laboratory Animals (237).
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Diets
AI N-93G powdered diet (Dyets, Inc., Bethlehem, PA, USA) was used as
the base diet. Experimental diets were prepared weekly by thoroughly mixing
resveratrol (Sigma Chemical Co., St. Louis, MO, USA) with the base diet to
homogeneity. Resveratrol concentrations in the diets were adjusted weekly,
based on food consumption and body weights to achieve doses of 0, 4, 20, and
90 mg per Kg body weight. Diets were prepared under yellow light and stored at 80 ° C under an atmosphere of nitrogen to minimize degradation of resveratrol.
Fresh diet was provided daily.

Experimental Design

Pharmacokinetics and absorption of resveratrol
To establish the stability of resveratrol in the diet, dietary samples
containing resveratrol at 750 ppm (dose equivalent to the animals fed 90 mg per
Kg body weight) (n=2) were stored under an atmosphere of nitrogen at -80° C
(controls), or exposed to experimental conditions (light and room temperature for
twenty-four hours). Samples were extracted with ethyl _acetate (x4) (Sigma),
evaporated under an atmosphere of nitrogen, re-suspended in the reversed
phase high pe_rformanc.� liquid chromatography (RP-HPLC) mobile phase and
analyzed for resveratrol content via RP-HPLC.
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To establish that resveratrol reaches the intestinal tract intact and is
subsequently absorbed, fifteen 1 0-week-old male C57BU6J mice were provided
resveratrol in the diet at a dose of 200 mg per Kg body weight. Before sacrifice,
the an imals were divided into five groups (n=3/g roup) . After six days on the diet,
blood was collected post-prandially via cardiac punctu re (under general
anaesthesia) at 5, 1 5 , 30, 60 and 90 min utes, and plasma resveratrol content
was analyzed via RP-H PLC . In a fol low-up experiment, three 1 0-week-old
C57BU6J wild type mice were fed resveratrol at 90 mg per Kg body weight. After
six days of feeding, blood was collected 30 min utes post-prandially and samples
were analyzed for resveratrol content via RP-HPLC .

Effect of resveratrol o n intestinal tumorigenesis in the

Minl+

Apc

mouse ·

model

Twenty-five male C57BU6J Ap�inl+ mice (43 days of age) were assigned
to fou r groups (6-7 mice per group) and fed diets supplemented with resveratrol
at 0, 4, 20 and 90 mg per Kg body weight for seven weeks, until 85 days of age .
Tumor n umber, size, and location we re determined with the use of a dissecting
microscope . Whole blood was collected via cardiac puncture, and immediately
placed on ice protected from light. Plasma was isolated and stored at -80 ° C for
analysis of resveratrol via RP-HPLC.
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Effects of Resveratrol on COX-2 levels and PGE2 biosynthesis in tumors
To establish the effect of resveratrol on COX-2 levels and PGE2
biosynthesis in tumors, 16 male C57BU6J AprfiAinl+ mice were assigned to a
control or experimental group (n=8) and fed resveratrol at a dose of O or 90 mg
per Kg body weight for seven weeks. At 87 days of age, animals were sacrificed
and excised intestinal tumors were analyzed for COX-2 expression and basal
PGE2 levels.

RP-H PLC analysis of trans-resveratrol
Resveratrol levels were analyzed by RP-HPLC using a Hewlett Packard
1090 Series-2 Liquid Chromatograph (Hewlett Packard, Paolo Alto, CA, USA)
equipped with a 25 cm, 4.6mm KR100-5C18 Kromasil RP-HPLC column (Akzo
Nobel - EKA Chemicals, Bohus, Sweden) with an isocratic mobile phase
consisting of 70% CH3CN, 30% MeOH, 0.1% glacial acetic acid (Sigma), at a
flow rate of 0.5 ml/min. Samples were monitored at 306 nanometers (nm) using a
photodiode array detector. Maximum absorption of resveratrol is reported at
306nm (238). Detection and spectrophotometric identification limits were 2ng and
3ng, respectively.

Extraction of resveratrol from plasma
To determine relative levels of free versus glucuronidated resveratrol in
the plasma, whole blood was collected via cardiac puncture, using
ethylenediaminetetraacetic acid (EDTA), (Life Technologies, Grand Island, NY,
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USA) at a concentration of 7.5% as an anti-coagulant, and immediately placed
on ice, protected from light. Plasma was isolated by centrifugation at 500 x g, 4 °
C for 15 minutes. To determine relative levels of resveratrol circulating in the free
form, 200 µI of plasma were aliquoted into an eppendorf tube, diluted 1 : 10 with
MeOH, adjusted to a pH of 3.5 with formic acid, and samples were subjected to
solid-phase extraction using a conditioned C18 cartridge (Burdick and Jackson,
Ml, USA). Resveratrol was eluted from the column (x2) with 2 ml of 100% HPLC
grade methanol (Sigma), evaporated under an atmosphere of nitrogen, re
suspended in the RP-HPLC mobile phase, and analyzed via RP-HPLC.
To determine relative levels of resveratrol circulating as the glucuronide
derivative, 200 µL of plasma were aliquoted into an eppendorf tube for enzymatic
hydrolysis via �-glucuronidase. Powdered H-1 �-glucuronidase (Sigma, St Louis,
MO, USA) was solubilized at 50 mg/ml in 0.2 mol/L sodium acetate buffer, pH
5.0 at 37° C. This enzyme solution was added to plasma at 5:1, to a final
concentration of 0.04 g/ml, and final specific activity of 5x103 µg/min/mg protein.
Samples were incubated for 2 hours at 37° C in a rocking incubator. The reaction
was terminated with 1 00% methanol, pH 3.0 with formic acid, to a final volume of
10% MeOH. Samples were extracted (x3) with equal volumes of ethyl acetate
(Sigma) and pooled organic phases were evaporated under nitrogen, re
suspended in 1 ml 10% aqueous methanol solution, and passed thru a 0.45µ
filter (Pall Corporation, Ann Arbor, Ml, USA). Resveratrol was isolated via solid
phase extraction as described previously and analyzed via RP-HPLC.
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lmmunohistochemistry for COX-2 expression
This analysis was conducted by Leah Rainwater. The tissues were
formalin-fixed, embedded in paraffin, and sectioned at 4 µM. Tissue sections
were then heated, de-paraffinized in xylene, re-hydrated in graded alcohols to
phosphate buffered saline (PBS) (3x, 5 minutes each), and pre-treated at or just
below boiling with 10 mmol/L citrate buffer, pH 6, for 10 minutes. Endogenous
peroxidase activity was quenched by incubation in 3% H202 PBS for 15 minutes
at room temperature and incubated for 30 minutes at room temperature with
protein block (Biogenex, San Ransom, CA). Slides were then incubated at 20 ° c
for 1 hour with affinity-purified rabbit polyclonal anti-mouse COX-2 lgG (1 :200)
(Cayman Chemical), followed by biotinylated anti-rabbit lgG (30 minutes at room
temperature) and streptavidin/biotin-horseradish peroxidase complex (30 minutes
at room temperature) which was localized by reaction with 3,3'-diaminobenzidine
tetra-hydrochloride (Biogenex) (0.7 mg/ml) and 0.05% H202 in 80mmol/L Tris
HCI, pH 7.6, for 1O minutes. Both positive and negative slides were lightly
counterstained with Mayer's hematoxylin. Staining for COX-2 protein was
evaluated from coded slides and scored blindly by a pathologist based on
distribution (extent) and relative staining intensity. Relative staining distribution
was scored as follows:
0 = < 10 stained cells per high power field (0.2 mm2 at 400x
magnification)
1 = 10-20 stained cells per high power field
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2 = 20-30 stained cells per high power field
3 = > 30 stained cells per high power field
Both positive and negative tumors (i.e. distribution = 0) were included in
calculating mean scores for each group. Relative staining intensities were graded
as follows:
0 no staining
1 representing perinuclear staining
2 representing stain extending to the cytoplasm
3 indicating a stain which obscured the cell nucleus
Intensity and distribution scores were then adde9 to generate a final value
corresponding to COX-2 expression.The reported staining scores represent the
sum of intensity and distribution ± SEM.
Basal PGE2 Levels
To determine the effect of resveratrol on PGE2 levels in tumors, intestinal
tumors from Ap<Jfinl+ mice fed resveratrol in the diet at O or 90 mg per Kg body
weight resveratrol in the diet were excised on dry ice, snap frozen in liquid
nitrogen, and stored at -80° C. At the time of analysis, tumors were pooled from
each animal and homogenized using a Polytron handheld homogenizer on ice at
10:1 in ice-cold 0.1 mol/L Tris-HCI buffer, pH 7.4. An aliquot of 50 µI from each
group was used for protein determination via the Bradford assay (246). PGE2
levels were determined by enzyme immunoassay (EIA) using the Correlate-EIA
PGE2 Kit (catalog # 900-001), (Assay Designs) according to the manufacturer's
instructions.
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Statistical analyses
Statistical analysis was carried out using the Statistical Analysis System
and JMP software (SAS Institute, Inc, Cary, NC, USA). Data was checked for
normality of distribution and homogeneity among variances. Differences in body
weight, diet intake, tumor number and basal PGE2 levels were analyzed by
student's t-test or one-way ANOVA. Differences among groups were detected
using Fisher's least significant difference at P< 0.05. Data are expressed as
means ± SEM.

Results
No significant differences in food intake were observed between any of the
treatment groups. During the last week of treatment, animal weights in the control
group were significantly lower when compared to the low-dose treatment group
(4 mg per Kg body weight). No other groups were significantly different.
To determine the general stability characteristics of resveratrol when exposed to
ultra-violet (UV) light, and to identify the absorption spectra of UV degradation
products of resveratrol, a solution containing resveratrol solubilized in the RP
HPLC mobile phase was analyzed by RP-HPLC, revealing a retention time of
4.693 minutes (Figure 11-1a, p. 38) and the standard UV absorption spectra of
resveratrol (Figure 11-1b, p. 38). This solution was then exposed to constant UV
light for 18 days and analyzed via RP-HPLC every 2 days for its degradation
products. Resveratrol was stable up to 14 days. After 14 days, two additional
peaks were observed at 4.578 and 5.228 minutes (Figure 11-2 a, p. 39),
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corresponding to two resveratrol isomerization products (240) identifiable by
distinct UV absorption spectra (Figure 11-2.b, p. 39, Figure 11-2.c, p.40). No
isomerization products of resveratrol were detected in the diet when it was
exposed to the same conditions present in the feeding study (Figure 11-3.a, p. 41 ,
Figure 11-3.b, p. 41, Figure 11-3.c, p. 42, Figure 11-3.d, p. 42), suggesting that
resveratrol remained stable in the diets under experimental conditions (Table 111, p. 50).
When non-hydrolyzed plasma of animals fed resveratrol at 200 mg per Kg
body weight was analyzed, the RP-HPLC chromatogram reveals a peak at 4. 74
minutes (Figure 11-4.a, p.43), however no UV absorption spectrum of resveratrol
was identifiable at that retention time (Figure 11-4.b, p. 43). Resveratrol was
detected in the plasma of animals following hydrolysis of the glucuronide
derivative at 200 mg per Kg body weight at 4. 720 minutes (Figure 11-4.c, p. 44,
Figure 11-4.d, p. 44) and at 90 mg per Kg body weight at 4.661 minutes (Figure
11-4.e, p. 45, Figure 11-4.f, p. 45). No resveratrol was detected in the plasma of
animals when not provided orally. Pharmacokinetic data from hydrolyzed plasma
revealed that plasma resveratrol was detected within 5 minutes, peaked by 30
minutes and was maintained for at least 90 minutes, post-prandially (Figure 11-5,
p. 46).
In comparison to untreated controls, resveratrol had no effect on intestinal
tumor load when provided in the diets of APC'1inl+ mice from 4-90 mg per Kg body
weight (Figure 11-6, p. 47). A second experiment yielded similar results, with no
significant difference in tumor load observed between animals fed 0 and 90 mg
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a. RP-HPLC chromatogram of non-hydrolyzed plasma extracted from animal fed
resveratrol at 200 mg/Kg BW.
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e. RP-H PLC ch romatogram of hyd rolyzed resveratrol extracted from plasma of
animal fed 90 mg per Kg BW, 30 minutes post-prandial time.
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Figure 1 1-5.

Effect of post-prandial time (5, 15, 30, 60, 90 minutes) on

plasma resveratrol levels after administration of 200 mg per Kg BW dose as
compared to controls (0 mg per Kg BW dose).
Plasma was collected and analyzed as described in materials and methods.
Error bars indicate ± SEM, n=3. Different superscripts indicate statistical
significance at p< 0.05.
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Figure 11-6. Effect of dietary resveratrol on intestinal tumor number in
APC Min/+ mice.
Resveratrol was administered to animals at 0-90 mg per Kg BW. Tumors were
analyzed as described in materials and methods. Values are means ± SEM, n=67. Different superscripts indicate differences among groups at p<0.05.

47

resveratrol per Kg body weight (Table 11-2 , p. 51). Basal PGE2 levels in tumors of
animals fed resveratrol at 90 mg per Kg body weight were measured by EIA as
an index of relative COX activity compared to the control animals (0 mg
resveratrol per Kg body weight). PGE2 levels of intestinal tumors were
significantly lower in the resveratrol-treated animals as compared to controls
(Table 11-2). There was no significant difference in COX-2 protei� levels between
the control animals (mean score = 0.69 ± 0.20) and animals fed resveratrol at 90
mg per Kg body weight (mean score + 1.09 ± 0.24) (Figure 11-7, p. 49). COX-2
localization was constrained to the stromal cells of the tumor with no detectable
levels in the epithelium. This confinement of COX-2 expression to stromal cells
as opposed to neoplastic epithelium has been reported previously ( 1 13) and
suggests that prostaglandins may exert their pro-tumorigenic effects via
paracrine signaling.

Discussion
Resveratrol's chemotherapeutic effects in vitro are believed to be related,
in part, to inhibition of COX-2 expression and activity (1 90), and these same
biochemical pathways are linked to intestinal tumorigenesis in Ap�inl+ mice (125,
230, 241). However, we report that resveratrol (0-90 mg per Kg body weight)
failed to decrease the number of intestinal tumors following seven weeks of
treatment.
Analysis of the diets revealed that resveratrol remained stable during the
time of feeding, and plasma pharmacokinetic data indicated adequate
48

Figure 1 1-7. Effect of dietary resveratrol on COX-2 expression in
intestinal tumors of APC Min/+ mice.
Representative photomicrograph of small intestinal tumor
immunohistochemically stained for COX-2 enzyme expression in an
animal treated with resveratrol. Arrows indicate positive (brown) COX-2
expression in stromal cells. Original magnification 400X.
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Table 11-1. Stability of resveratrol in animal diets under 24- hour
experimental conditions as compared to non-exposed controls
Exposed D iet

Control Diet

% Control

1 008

Resveratrol was extracted from experimental and control diets and measu red via
RP-HPLC as described in materials and methods. Values are expressed as
percent of control. a There was no sign ificant d ifference in levels of trans
resveratrol between control and exposed d iets at p< 0.05.
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Table 11-2. Effect of dietary resveratrol at 90 vs 0 mg per Kg BW on tumor
number and tumor PGE2 biosynthesis

Resveratrol dose in mg/Kg BW

0

90

Mean tumor #

32.86 ± 5.568

25.86 ± 5.888

pg PG E2/mg protein

1.32 ± 0.628

0.78 ± 0.62 b

1

Intestinal tumors were analyzed for PGE2 levels as described in materials and

methods. Values are expressed as means ± SEM. Different superscripts in each
row indicate statistically significant differences among groups at p<0.05.
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absorption. Resveratrol and other polyphenols are absorbed in the small
intestines where they undergo glucuronidation before appearing in the blood
(242). Our data demonstrate that 100% of resveratrol exists as the glucuronide
conjugate in the circulation. However, there is much debate as to whether this
form of resveratrol is biologically active. In vitro studies utilize the free form of
resveratrol and derivatization in vivo could result in a less biologically active
compound. Furthermore, studies in vivo are lacking as to whether there is
adequate �-glucuronidase activity to generate sufficient levels of free resveratrol
in vivo to mimic the in vitro results. We observed no measurable levels of free
resveratrol in the plasma of resveratrol-treated mice, and resveratrol was only
detected following enzymatic hydrolysis, consistent with complete
glucuronidation. Human and rat small intestines have sufficient �-glucuronidase
activity to hydrolyze naturally occurring glucuronide derivatives of polyphenols
found in the diet, but it does not appear that this activity is sustained within the
circulation (243-245). Resorcin-containing polyphenols such as resveratrol,
quercetin, and catechins display similar pharmacokinetics to the kinetics
observed here, with peak plasma levels occurring at approximately ½ -1 hour
post-ingestion, and others have confirmed that greater than 95% of all of these
compounds circulate in the plasma in their conjugated forms (139, 246-248).

We failed to observe any reduction in tumor load with dietary levels of
resveratrol that ranged from 4 to 90 mg per Kg body weight. These results are in
contrast to a previous paper reporting a 74% reduction in tumor frequency in this
52

model when a comparable dose of resveratrol was provided in the drinking water
dissolved in ethanol (249). While ethanol may increase �-glucuronidase activity
in tissues such as liver and lung (250-252), it appears that the presence of
ethanol as a vehicle used in the oral administration of polyphenols, does not
increase the ability of the intestinal tract to hydrolyze glucuronide derivatives
(139). Therefore, providing resveratrol in the diet or drinking water dissolved in
ethanol should not increase circulating levels of the free form of the compound
and cannot explain the disparate results observed between the two studies. In an
effort to duplicate our results, we repeated the study using the highest dose (90
mg per Kg body weight), and again observed no significant decreases in tumor
load with dietary resveratrol.

Furthermore, our results confirm that resveratrol was absorbed and
reached the target tissue as evidenced by reductions in PGE2 biosynthesis in
tumors of resveratrol-fed animals as compared to controls. The doses
administered are comparable to doses administered in a previous study (249)
and the length of the study (seven weeks) should have been adequate to
observe any decreases in tumor load. Our estimated concentration of 131uM/L
for total plasma resveratrol (90 mg per Kg body weight group) far exceeds the
plasma levels (1.5uM/L) from a volunteer given a 25 mg oral dose ( ~0.4 mg per
Kg body weight for a 70 Kg individual) (244). To fully appreciate these doses,
the amount of resveratrol in a liter of table wine varies from 0.1-7.7 mg (240).
Most wines, however, contain concentrations that are less than 0.5 mg/L (240).
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Discordant effects on resveratrol's ability to modify tumorigenesis have
been reported elsewhere, particularly when comparing results in vitro versus in
vivo. Resveratrol inhibited the in vitro growth of 32Dp210 mouse myeloid
leukemia cells and resveratrol-pretreated cells implanted subcutaneously;
however, when the same cell line was implanted subcutaneously without pre
treatment and mice were given resveratrol orally, no inhibition of growth was
observed (4). Similarly, orally-administered resveratrol failed to inhibit
tumorigenesis in a chemically-induced lung tumor model (253). Yet, resveratrol
has been shown to inhibit tumorigenesis in a carcinogen-induced rat model of
colon cancer (220), Lewis lung carcinoma-bearing mice (254), and in a DMBA
induced mammary tumor mouse model (229). Similarly, dichotomous results
have been reported with other structurally related polyphenolic compounds. For
· example, quercetin was unable to reduce the number of tumors in Apd-'1in1+ mice,
· but effectively reduced tumor load in a murine model of carcinogen-induced
colon cancer (147). Like.wise, genistein inhibited the growth of MDA-MB-231
cells (255) in vitro, but was ineffective when the cells were implanted in mice that
were given genistein orally (256). These disparate results make it difficult to
predict the in vivo effects of this compound at human equivalent doses.
We investigated the effect of resveratrol on PGE2 biosynthesis and COX�2
expression in intestinal tumors because we, and others, have established that
COX inhibition reduced the growth of intestinal tumors and regressed established
tumors in this animal model as reviewed by Whelan and McEntee (257).
Chemopreventive agents containing a common resorcin moiety (e.g., resveratrol,
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quercetin, genistein) suppressed COX-2 transcription and activity in a human
colon cancer cell line (224) and selective inhibition of COX-2 inhibited
tumorigenesis in Apd'inl+ mice (258). Resveratrol inhibited COX-2 transcription
and directly inhibited COX-2 activity in vitro (192, 259). We failed to observe any
difference in COX-2 expression as a result of resveratrol treatment. However, we
did detect PGE2 levels that were 41% lower in tumors from the resveratrol-fed
animals, but this change was apparently insufficient to impact tumor number.
Inhibition of PGE2, viewed as an isolated event, is not always associated with a
reduction in tumors (241, 260).

Summary and Concl usions
In summary, resveratrol was shown to be stable in the diet, was absorbed
intact and reached the target tissue, but had no effect on intestinal tumorigenesis
at 3 doses and in two independent experiments. These results may be explained,
in part, by the fact that 1) resveratrol was ineffective as a modulator of COX-2
expression in tumors, 2) the decreases in PGE2 formation were insufficient to
modify tumor integrity, and/or 3) the levels of free resveratrol did not attain a
sufficient concentration to duplicate the antitumorigenic effects observed in vitro.
Further experimentation is required to investigate the seemingly inconsistent
effects of resveratrol using in vivo versus in vitro models.
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APPENDIX
A-1
Ingredient
Casein
Cornstarch
Dyetrose
Sucrose
Cellulose
Soybean Oil .
tButylhydroquinone
Salt mix# 21 0025
Vit mix# 31 0025
L-Cystine
Choline Bitartrate

g/Kg

KcaVg

200
397.486
1 32
1 00
50
70
0.01 4
35
10
3
2.5

3.58
3.6
3.8
4

Kcal/Kg
71 6
1 430.95
501 .6
400

9

630

0.88
3.87
4

30.8
38.7
12

Total

3760.05

A-1. Nutrient Composition of AI N-93G diets

A-2

Resveratrol Standard curve
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